Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 24685910)

1.

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Mercer LK, Lunt M, Low AL, Dixon WG, Watson KD, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium.

Ann Rheum Dis. 2015 Jun;74(6):1087-93. doi: 10.1136/annrheumdis-2013-204851. Epub 2014 Mar 31.

2.

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941.

3.

Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.

Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.

Int J Rheum Dis. 2012 Jun;15(3):330-5. doi: 10.1111/j.1756-185X.2012.01715.x. Epub 2012 Feb 13.

PMID:
22709496
4.

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.

Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R; ARTIS group.

Ann Rheum Dis. 2015 May;74(5):890-6. doi: 10.1136/annrheumdis-2013-204714. Epub 2014 Jan 15.

PMID:
24431398
5.

The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.

Ljung L, Askling J, Rantapää-Dahlqvist S, Jacobsson L; ARTIS Study Group.

Arthritis Res Ther. 2014 Jun 18;16(3):R127. doi: 10.1186/ar4584.

6.

Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register.

Ann Rheum Dis. 2011 Oct;70(10):1831-4. doi: 10.1136/ard.2011.153536. Epub 2011 Jul 22.

7.
8.

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR.

Ann Rheum Dis. 2009 Feb;68(2):209-15. doi: 10.1136/ard.2007.087288. Epub 2008 Apr 2.

9.

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP; British Society For Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register.

Arthritis Care Res (Hoboken). 2010 Jun;62(6):755-63. doi: 10.1002/acr.20129. Erratum in: Arthritis Care Res (Hoboken). 2010 Oct;62(10):1514.

10.

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.

Mercer LK, Green AC, Galloway JB, Davies R, Lunt M, Dixon WG, Watson KD; British Society for Rheumatology Biologics Register Control Centre Consortium, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register.

Ann Rheum Dis. 2012 Jun;71(6):869-74. doi: 10.1136/annrheumdis-2011-200622. Epub 2012 Jan 12.

11.

Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?

Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J; ARTIS Study Group.

Ann Rheum Dis. 2015 Jun;74(6):1212-7. doi: 10.1136/annrheumdis-2013-204960. Epub 2014 Mar 7.

PMID:
24608401
12.

Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.

Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Walker D, Kelly C, Birrell F, Chakravarty K, Maddison P, Heslin M, Patel A, Kingsley GH.

BMJ. 2015 Mar 13;350:h1046. doi: 10.1136/bmj.h1046.

14.

Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.

Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Kalstad S, Kaufmann C, Rødevand E, Kvien TK.

Ann Rheum Dis. 2011 Dec;70(12):2103-10. doi: 10.1136/ard.2011.152363. Epub 2011 Aug 28.

PMID:
21875874
15.

Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.

Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Ma M, Walker D, Heslin M, Patel A, Kingsley G.

Health Technol Assess. 2014 Oct;18(66):i-xxiv, 1-164. doi: 10.3310/hta18660.

16.
17.

Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register.

Simard JF, Neovius M, Askling J; ARTIS Study Group.

Arthritis Rheum. 2012 Nov;64(11):3502-10. doi: 10.1002/art.34582.

18.

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.

Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group.

J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15.

PMID:
21498482
19.

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A; B S R B R Control Centre Consortium, Symmons DP; BSR Biologics Register.

Ann Rheum Dis. 2010 Mar;69(3):522-8. doi: 10.1136/ard.2009.118935. Epub 2009 Oct 22.

20.

Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.

Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, Saag KG, Beukelman T, Winthrop K, Baddley JW, Curtis JR.

Ann Rheum Dis. 2015 Jun;74(6):1065-71. doi: 10.1136/annrheumdis-2013-204011. Epub 2014 Mar 7.

PMID:
24608404
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk